凯尼克萨制药

最新新闻

• 评级变动
  Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $74
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  A Quick Look at Today's Ratings for Kiniksa Pharmaceuticals International(KNSA.US), With a Forecast Between $57 to $71
  \u5e02\u573a\u8d44\u8baf · 2026/4/29
• CCORF Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $98
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $53
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/1/13
• Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $72
  \u5e02\u573a\u8d44\u8baf · 2026/6/29
• 评级变动
  Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2025/12/12
• 评级变动
  Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $53
  \u5e02\u573a\u8d44\u8baf · 2026/2/25
• 评级变动
  TD Cowen Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/2/25
• A Quick Look at Today's Ratings for Kiniksa Pharmaceuticals International(KNSA.US), With a Forecast Between $87 to $107
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• Wells Fargo Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $87
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $75
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  CCORF Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $62
  \u5e02\u573a\u8d44\u8baf · 2026/2/19
• 评级变动
  Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $58
  \u5e02\u573a\u8d44\u8baf · 2026/4/16
• 评级变动
  Citi Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/1/30
• 评级变动
  Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $59
  \u5e02\u573a\u8d44\u8baf · 2026/4/29
• 评级变动
  J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $68
  \u5e02\u573a\u8d44\u8baf · 2026/3/14
• 评级变动
  CCORF Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $62
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $72
  \u5e02\u573a\u8d44\u8baf · 2026/5/4

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。